Stem cells are increasingly important for future health.

Vita34 is working in an exciting area: stem cerlls, umbilical or otherwise, are now so important in so many areas of health, for everyone, not just children.

Even joint replacements like hips and knees may one day become unnecessary when stem cell treatments are able to replace lost cartilage. And recovery after cancer treatments are helped by using umbilical stem cells to regrow damaged body parts. And so much more...

I own Vita34, and add whenever a fallback in price gives a buying opportunity. This business will, like its stem cells, grow and grow and grow!

Thanks

Girl is cured of leukemia using stem cells from umbilical cord

Germany, November 30, 2010

Girl is cured of leukemia using stem cells from umbilical cord


Scientist Leipzig City confirmed ‘to have cured for the first time lymphoblastic leukemia with a transplant of stem cells from the umbilical cord of a nine years old girl. Life expectancy of the patient, who was suffering for three years, was reduced to three months before treatment was successful. ”
Vita 34, a company founded in 1997 by doctors at the eastern Germany city of Leipzig, announced this big news that was hopeful.
According to German experts, “the disease was diagnosed in the German girl at the age of three years and, after being treated with chemotherapy, it was found that their only chance of survival lay in a stem cell transplant.”
Dr. Eberhard Lampeter, medical director of Vita 34 explained that, “The life expectancy of the patient was reduced to three months without a stem cell therapy,” and said, “the cancer cells had already reached the brain.”
He also noted that “parents of the girl at the time of her birth decided to keep her umbilical cord, which was used to extract stem cells needed for her transplant.”
The professional said that “within 75 months from the intervention and now we can speak with certainty of a cure.”
According to the company, “A total of 15 children, including six with brain damage, could be treated so far with stem cells from their umbilical cords.”
Vita 34, also engaged in research on aging, multiplication and stem cell reprogramming and developing new stem cell based therapies to treat type 1 diabetes, brain damage and heart disease.

For the first time healing a leukemia by the own umbilical cord blood

Erstmals Heilung einer Leukämie durch das eigene Nabelschnurblut


VITA 34 Article

Thank You ! http://www.microsofttranslator.com/Default.aspx?ref=IE8Activity Umbilical cord blood may reduce inflammation stem cells from umbilical cord blood could in future rheumatism help. Chinese scientists are convinced. At least in the laboratory of cell samples and in animal studies in mice, the stem cells have proven their healing potential. The researchers had mixed with foreign stem cells from umbilical cord blood of rheumatism patients. This undifferentiated cells dampened the inflammation by they calmed certain cells of the immune system are overactive when suffering, so to speak. In the second part of the investigation the Chinese researchers mice suffering from rheuma-like arthritis treated, with stem cells from human umbilical cord blood. Rodents could move to regain it. The inflammation decreased measurably. Unlike medicines available today, the treatment with stem cells could permanently improve the disease, the researchers say.

This isnt Furniture here!

Nabelschnurblut kann Entzündungen dämpfen

Stammzellen aus dem Nabelschnurblut könnten in Zukunft Rheumatikern helfen. Davon sind chinesische Wissenschaftler überzeugt. Zumindest im Laborversuch an Zellproben und im Tierversuch an Mäusen haben die Stammzellen ihr heilendes Potenzial bewiesen. Die Forscher hatten Blut von Rheuma-Patienten mit fremden Stammzellen aus Nabelschnurblut vermischt. Diese undifferenzierten Zellen dämpften die Entzündung, indem sie bestimmte Zellen des Immunsystems, die bei dem Leiden überaktiv sind, sozusagen beruhigten. Im zweiten Teil der Untersuchung behandelten die chinesischen Forscher Mäuse, die an rheumaähnlichen Gelenkentzündungen litten, mit Stammzellen aus menschlichem Nabelschnurblut. Die Nager konnten sich darauf hin wieder besser bewegen. Die Entzündungen gingen messbar zurück. Im Gegensatz zu heute erhältlichen Medikamenten könne die Therapie mit den Stammzellen die Krankheit dauerhaft bessern, sagen die Forscher.

No News!

Nice here!

Still no chart.

Please request chart here. Ask for ticker VTIAF and use otc since that is how it is traded in US. TIA

http://stockcharts.com/help/doku.php?id=support:feedback:symbol_request

Please request chart here. Ask for ticker VTIAF
http://stockcharts.com/help/doku.php?id=support:feedback:symbol_request

VITA34
INTERNET: www.vita34.de, Email info@vita34.de
PHONE: +49 (341) 4879290
OFFICE: Leipzig, Germany
STORAGE: Leipzig, Germany

COMMENTS:
•VITA34 was the first family cord blood bank on the European continent.
•VITA34 was the first private bank in the world to provide insurance that guarantees storage if the company goes out of business.
•VITA34 is the first family bank in Europe to offer parents the option of donating their child's cord blood if it matches a patient needing a transplant.

•Website in German and English.


SERVICES & DISCOUNT OPTIONS:
•The first transplant in Europe using privately banked cord blood took place on 26 Sept 2005. The blood had been stored at VITA 34 on 8 Feb 2005 and was transplanted to treat a 5 year old brother with aplastic anemia.
•11 transplants; 8 to the baby whose blood was banked (ie: autologous)

•VITA 34 moved to a new building in Leipzig in Aug 2003: it features a glass laboratory where visitors can observe cord blood processing in a clean room.

•VITA 34 has applied for a patent (Feb 2006) on their sterile technique of processing cord blood. The new VITA 34 system maintains sterility from collection through processing and storage.
•Collection kit contains extra disinfection supplies. Collection training provided at 2-3 hospitals per week.
•Cost includes temperature-controlled courier transport by express train

•Transport box includes electronic chip to monitor temperature.
•VITA 34 contract is for indefinite storage, not just 18 or 20 years.

•Traditional price model for "Vita 34 Klassik" is an all-inclusive fee of Euro 1990 for collection and processing; the annual storage fee is Euro 30 per year.

•Additional product: "Vita 34 Max", including several medical precautionary services for Euro 2490 plus annual fee of Euro 30
•Another alternative is to pay 25 years of storage in advance for Euro 2490 for "Vita 34 Klassik", resp. Euro 2990 for "Vita 34 Max"; saving Euro 250.
•Additional service: VitaplusDonation (combination of private and public storage)

•If the sample fails infectious disease testing, there is no charge to parents. If the sample can be stored but the parents choose not to store, only Euro 150 charged.
•Parents can cancel their contract within 4 weeks of collection without cause.
•Listed price is for Germany and Austria; elsewhere cost adjusted to cover transportation.
•Sibling Transplant Program provides free banking if a sibling has a disease that is treated with transplantation. As of May 2004, 70 children have banked cord blood under this charity program.
•VITAplusDonation (available starting 1 Jan 2008) gives parents the option to undergo further typing and testing and list the cord blood on a registry. If the cord blood matches a patient needing a transplant, parents can choose to donate the cord blood to the patient and receive reimbursement from the bank.
•The fact that VITA 34 is allowed to transfer private clients to public donations shows that their quality control meets all the requirements for public banking.

•As of 30 June 2009, VITA 34 claims an inventory of 63,000 cord blood collections.


ADDITIONAL INFORMATION:
VITA 34 has several research partners. Topics of research include:
•cord blood expansion
•cord blood treatment of stroke
•cord blood treatment of myocardial infarction
•cord blood treatment of newborn brain disease
•cord blood treatment of type-1-diabetes (juvenile diabetes)

•basic stem cell research, e.g. on very small embryonic like stem cells

On 23 March 2007, VITA 34 International AG became a publicly traded company. The release of 600,000 shares at 15 Euro each created a cash inflow of 9 million Euro to fuel accelerated growth. VITA34 is listed on the Frankfurt stock exchange, all shares are graded "prime". VITA 34 estimates that nearly 90% of families storing cord blood in Germany are using their services.

VITA34 is one of the first private banks in the world to combine family storage with public donation, through their VITAplusDonation program. Previously, CryoLife in Hong Kong offered the CryoMATCH service, whereby parents could agree to have the blood listed on a registry and parents made the decision whether to release it if it matched a patient. Then Virgin Health Bank in the UK started a program whereby the parents kept 20% of the cord blood and 80% went into a public bank. In the VITAplusDonation program, the cord blood remians the property of the parents but it undergoes the testing and typing that allow it to be available to a patient needing a transplant. If parents choose to donate the blood they will be fully reimbursed by the bank. VITA 34 is the only private cord blood bank in Germany which has a pharmaceutical permit for the storage of donated cord blood intended for unrelated patients (called allogeneic transplants). This program fills the desire of parents to be able to help their own family and society at the same time. VITA34 is one of the founding members of Cord Blood Europe.

DGAP-Adhoc: VITA 34 International AG: (English version for those that don't speak German)

VITA 34 is back in the black again in 2009 http://www.tradesignalonline.com/Markets/Story.aspx?id=576026&cat=1

VITA 34 is back in the black again in 2009

* EBIT of plus EUR 0.2 million
* Group result of plus EUR 0.6 million
* Operating cash flow of plus EUR 1.1 million

Leipzig, February 22, 2010 - The VITA 34 International AG (ISIN
DE000A0BL849), parent company of the largest private umbilical cord blood bank in the German-speaking countries VITA 34, has made the return to the profit zone in the fiscal year 2009. After the EBIT had been forecast to reach the break-even, earnings before interest and tax at the amount of plus EUR 0.2 million could be achieved in the end. In the previous year, a loss of EUR 2.3 million had been recorded. In 2009, the group result of plus EUR 0.6 million had turned out even more positively mainly due to a good financial result, in comparison with a net loss of EUR 1.7 million in 2008. The revenue could be slightly increased from EUR 15.0 million to EUR 15.1 million in the business year 2009. The number of stored umbilical cord blood preparations of 10,816 was a little bit lower than the number reached in the year before of 11,020. For the first time in 2009, preparations from Slovenia and Italy were stored besides those from Germany and Spain at VITA 34 in Leipzig.

The operating cash flow in 2009 amounted to EUR 1.1 million after minus EUR 2.9 million in the previous year. The liquid funds added up to EUR 8.1 million at the end of the year, the equity ratio increased to 60.6 percent.

VITA 34 expects a clearly increasing profitability for the fiscal year 2010. It is an additional purpose to further develop the national and international network of partnerships this year.

The complete annual report will be available for download under
www.vita34.de in the Investor Relations section in the course of February 25, 2010.


Press / Investor Relations:
Axel Mühlhaus
Dr. Sönke Knop
Edicto GmbH
Zeißelstraße 19
D-60318 Frankfurt
Tel.: +49 (069) 90550550
Fax: +49 (069) 90550577
eMail: vita34@edicto.de

VTIAF is the ticker to use in the US if one wants to trade this. ;)

And, keep in mind the exchange rate.


Vita 34 International AG (frankfurt V3V, us VTIAF)

Below is why the nice jump. Annual report due out 2/25/10.


VITA 34 International AG / Final Results

22.02.2010 08:37

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

--------------------------------------------------------------------------------

VITA 34 is back in the black again in 2009

* EBIT of plus EUR 0.2 million
* Group result of plus EUR 0.6 million
* Operating cash flow of plus EUR 1.1 million

Leipzig, February 22, 2010 - The VITA 34 International AG (ISIN DE000A0BL849), parent company of the largest private umbilical cord blood bank in the German-speaking countries VITA 34, has made the return to the profit zone in the fiscal year 2009. After the EBIT had been forecast to reach the break-even, earnings before interest and tax at the amount of plus EUR 0.2 million could be achieved in the end. In the previous year, a loss of EUR 2.3 million had been recorded. In 2009, the group result of plus EUR 0.6 million had turned out even more positively mainly due to a good financial result, in comparison with a net loss of EUR 1.7 million in 2008. The revenue could be slightly increased from EUR 15.0 million to EUR 15.1 million in the business year 2009. The number of stored umbilical cord blood preparations of 10,816 was a little bit lower than the number reached in the year before of 11,020. For the first time in 2009, preparations from Slovenia and Italy were stored besides those from Germany and Spain at VITA 34 in Leipzig.

The operating cash flow in 2009 amounted to EUR 1.1 million after minus EUR 2.9 million in the previous year. The liquid funds added up to EUR 8.1 million at the end of the year, the equity ratio increased to 60.6 percent.
VITA 34 expects a clearly increasing profitability for the fiscal year 2010. It is an additional purpose to further develop the national and international network of partnerships this year.

The complete annual report will be available for download under www.vita34.de in the Investor Relations section in the course of February 25, 2010.


Press / Investor Relations:
Axel Mühlhaus
Dr. Sönke Knop
Edicto GmbH
Zeißelstraße 19
D-60318 Frankfurt
Tel.: +49 (069) 90550550
Fax: +49 (069) 90550577
eMail: vita34@edicto.de

DGAP-Adhoc: VITA 34 International AG (deutsch)
Date : 02/22/2010 @ 2:37AM
Source : DPA Reg News (German)
Stock : Vita 34 International Ag (V3V)
Quote : 5.52 0.86 (18.45%) @ 11:32AM


DGAP-Adhoc: VITA 34 International AG (deutsch)
VITA 34 International AG: VITA 34 erzielt Rückkehr in die schwarzen Zahlen im Geschäftsjahr 2009 VITA 34 International AG / Jahresergebnis 22.02.2010 08:36 Veröffentlichung einer Ad-hoc-Mitteilung nach § 15 WpHG, übermittelt durch die DGAP - ein Unternehmen der EquityStory AG. Für den Inhalt der Mitteilung ist der Emittent verantwortlich. --------------------------------------------------------------------------- VITA 34 erzielt Rückkehr in die schwarzen Zahlen im Geschäftsjahr 2009 * EBIT bei plus 0,2 Mio. Euro * Konzernergebnis bei plus 0,6 Mio. Euro * Operativer Cashflow plus 1,1 Mio. Euro Leipzig, 22. Februar 2010 - Die VITA 34 International AG (ISIN DE000A0BL849), die Muttergesellschaft der größten privaten Nabelschnurblutbank im deutschsprachigen Raum VITA 34, hat im Geschäftsjahr 2009 die Rückkehr in die Gewinnzone geschafft. Nachdem beim EBIT eine schwarze Null prognostiziert worden war, konnte letztlich ein Ergebnis vor Steuern und Zinsen von plus 0,2 Mio. Euro erzielt werden. Im Vorjahr war noch ein Verlust von 2,3 Mio. Euro angefallen. Das Konzernergebnis fiel im Jahr 2009 mit plus 0,6 Mio. Euro vor allem aufgrund eines guten Finanzergebnisses noch deutlicher positiv aus, verglichen mit einem Nettoverlust von 1,7 Mio. Euro im Jahr 2008. Der Umsatz konnte im Geschäftsjahr 2009 leicht von zuvor 15,0 Mio. Euro auf 15,1 Mio. Euro gesteigert werden. Die Zahl der eingelagerten Nabelschnurblut Präparate lag mit 10.816 knapp unter dem Vorjahreswert von 11.020. Erstmals konnten 2009 neben Präparaten aus Deutschland und Spanien auch solche aus Slowenien und Italien bei VITA 34 in Leipzig eingelagert werden. Der operative Cashflow im Jahr 2009 belief sich auf 1,1 Mio. Euro nach -2,9 Mio. Euro im Jahr vorher. Die liquiden Mittel summierten sich Ende 2009 auf 8,1 Mio. Euro, die Eigenkapitalquote erhöhte sich auf 60,6 Prozent. Für das Geschäftsjahr 2010 geht VITA 34 von einer deutlichen Erhöhung der Profitabilität aus. Ziel ist es zudem, das nationale und internationale Kooperationsnetzwerk im laufenden Jahr weiter zu entwickeln. Der vollständige Geschäftsbericht steht im Laufe des 25.02.2010 unter www.vita34.de in der Investor Relations Sektion zum download bereit. Presse / Investor Relation: Axel Mühlhaus Dr. Sönke Knop Edicto GmbH Zeißelstraße 19 D-60318 Frankfurt Tel.: +49 (069) 90550550 Fax: +49 (069) 90550577 eMail: vita34@edicto.de 22.02.2010 08:36 Ad-hoc-Meldungen, Finanznachrichten und Pressemitteilungen übermittelt durch die DGAP. Medienarchiv unter www.dgap-medientreff.de und www.dgap.de --------------------------------------------------------------------------- Sprache: Deutsch Unternehmen: VITA 34 International AG Deutscher Platz 5a 04103 Leipzig Deutschland Telefon: +49(0341)48792-40 Fax: +49(0341)48792-39 E-Mail: info@vita34.de Internet: www.vita34.de ISIN: DE000A0BL849 WKN: A0BL84 Börsen: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Hamburg, Stuttgart Ende der Mitteilung DGAP News-Service ---------------------------------------------------------------------------

Please request chart here. Ask for ticker VTIAF

http://stockcharts.com/help/doku.php?id=support:feedback:symbol_request





"Be kinder than necessary, for everyone you meet is fighting some kind of battle."

You are very welcome locks. ;)





"Be kinder than necessary, for everyone you meet is fighting some kind of battle."

Yes. Very nice.

Have you looked in our Ibox yet.Thanks Karin

Here is another interesting connection between Vita34 and CBAI that Eco posted back in December.

Interesting bit of information!
As we all know Matt recently spent 10 days in Germany, and as I said earlier "I don't think he was site seeing".
Here is a link between CBAI and a German Cord Blood Bank.
They both have a common Board member. Jack Goldberg MD
There may be nothing to this but, I found it rather interesting! Any Thoughts?

www.vita34.de
Company Description

VITA 34 International AG, through its subsidiary, VITA 34 AG, operates as an umbilical cord blood bank in Germany. The company collects, processes, and stores stem cells from cord blood and to develop cell therapeutics. It involves in the recovery, preparation, and storage of blood and stem cell products for the treatment of various disease patterns. The company also offers parents the opportunity to store the umbilical cord blood of their children privately and if needed, for the treatment of a third-party recipient, to donate it. Vita 34 International AG was founded in 1997 and is headquartered in Leipzig, Germany.



Member of Scientific and Medical Advisory Board of VITA 34 INTERNATIONAL AG.
JACK GOLDBERG M.D. BACKGROUND*

Jack Goldberg, MD has been Medical Director of CorCell Inc. (which is now a Cord Blood America subsidiary) since 1996.
Dr. Goldberg serves as an Head of the Division of Hematology and Oncology of the University of Pennsylvania Health System, Presbyterian Medical Center. He serves as Head of the New Jersey Pain Initiative and continues to be active in research in hematopoiesis. Dr. Goldberg has been a Consultant to the National Cancer Institute. He served as the head ... of Cooper Cancer Institute and the Division of Hematology and Medical Oncology of the Cooper Health System since 1989. Dr. Goldberg also served as Medical Director of the Coagulation Laboratory, the Adult Hemophilia Center.

He serves as the Chairman of Scientific and Medical Advisory Board of CorCell Inc. Dr. Goldberg has been Chairman of Medical Advisory Board of Cord Blood America Inc. since May 3, 2007.

He serves as Member of Scientific and Medical Advisory Board of VITA 34 INTERNATIONAL AG. (Cord Blood Bank in Germany)

He serves as Co-Director of the Cooper Hospital Blood Bank. He serves as a board member of the American Cancer Society and the Leukemia Society, and HLA Registry. Dr. Goldberg serves on the faculty at SUNY Health Science Center and continued his career in academic hematology and medical oncology. He served as Professor of Medicine of the Robert Wood Johnson Medical School. He returned to SUNY Health Science Center in Syracuse and completed his fellowship in hematology and medical oncology. He has been an American Cancer Society Professor of Clinical Oncology for 10 years. Dr. Goldberg achieved the rank of an Associate Professor in Medicine and Pathology while actively pursuing research in hematopoiesis and disorders of the blood including leukemia and lymphoma. He served as professor of the Coriell Institute for Medical Research. He has a number of awards for distinguished service and teaching awards at both the SUNY Health Science Center in Syracuse, New York, and at Cooper Hospital University Medical Center. He is also the recipient of grants from the National Cancer Institute and the American Cancer Society. He has more than eighty publications in peer review journals. Dr. Goldberg completed his medical training at State University of New York (SUNY) Health Science Center in Syracuse, New York. After earning his medical degree, he completed an internship and residency at University Hospital in Boston, Massachusetts.

I'm not sure where the V3V came from but can't find it looking at the US market. Is this stock traded at all in the US and if so what is the symbol? Anyone. Thanks.

One more thing. I posted the change in management that happened in Vita 34 just before Matt arrived in Germany. I left my job and retired partly because I knew another company, AT&T, was buying my unit. So that too could be a signal? Just guessing though. The announcement said they were setting up the company to be more of a marketing and sales unit something consistent with a new HQ's.

Morning Locks. I haven't gone back to when Matt bought Corcell but based on what I'm seeing there were obviously shares involved. Truthfully, IMO if CBAI was to buy, merge, or whatever with Vita 34 I feel certain there would have to be a lot of shares involved. Doesn't bother me if we bought Vita and used shares but might bother others. But I feel sure CBAI would go up a bunch if this happened and surely set them up nicely in Europe. If Bluc Cross gives Vita 34 up to Matt they are going to want a 15-20% stake in CBAI. All along I've been convinced we're doing something in Germany and this make the most sense to me. No way Blue Cross is going to want Matt to start a competitor in Germany IMO. I'm also am thinking maybe Matt needed some of the shares he had already allocated to the S1 but just guessing. All of this is obviously speculation but what I presented are the various relationships that run deep between the two companies and those are very important to making deals.

Dew was Corcell bought with Dilution

July 2004, CorCell had merged with the German cord blood bank VITA34, under a German holding company VITA34 International AG. The acquisition by Cord Blood America severed the relationship between CorCell and VITA34.

http://www.healthycordblood.com/corcell-cord-blood-america/

A lot of co's, especially same sector, have BOD members that sit on numerous similar co's boards....its not unusual at all...

jmho

VITA 34 International AG restructures management team after returning to the black
Streamlined structure aimed at further increasing profitability
22 Oct 2009 - VITA 34 International AG has decided to restructure its management team after successfully returning to the black. This move is to lay the foundations for further increasing profitability in the coming years.


Dr. Eberhard Lampeter, founder and CEO of VITA 34 AG, will continue to head the company. Finance will be headed by Jörg Ulbrich in the future. Mr. Ulbrich was in charge of Administration at VITA 34 up to now and therefore has an in-depth insight into the company.

The previous CFO, Peter Boehnert, has requested to leave the company from October 31, 2009. He is now looking for a new challenge elsewhere. He leaves on good terms after successfully implementing cost reduction measures which were launched in mid 2008. The VITA 34 International AG Supervisory Board agreed to his request.

Oliver Papavlassopoulos has also announced that he will be stepping down from his position as Chief Marketing Officer on October 31, 2009. He is planning to work on a self-employed basis in the future. In the last few years, he has been highly successful in paving the way for VITA 34's internationalization. The new appointments in this area of the company represent a careful realignment of Marketing and Sales, and these measures are to create a better benefit-cost ratio. The overall aim is to support further earnings increases in the coming years.

http://www.bionity.com/news/e/108335/

Kind of old but well worth a read.


http://www.shsvc.net/download/Pressemitteilungen-Partner/Vita34-Initiating_coverage_12_July_2007.pdf

From last years 10K for CBAI.

Common 166,387,000

% Ownership 14.89

CorCell Inc. (7)

1717 Arch Street, Ste. 1410

Philadelphia, PA 19013

(7) Mr. Peter Boehnert exercises voting control of the shares.

http://app.quotemedia.com/quotetools/showFiling.go?webmasterId=89753&name=CORD BLOOD AMERICA, INC.: 10-K, Sub-Doc 1, Page 1&link=http%3A//quotemedia.10kwizard.com/filing.xml%3Frid%3D12%26ipage%3D6268716%26DSEQ%3D1%26SQDESC%3DSECTION_BODY%26doc%3D1&cp=off

These shares actually belong to Vita 34 International AG.


Map Peter Boehnert and Vita 34 International AG's 11 relationships


http://www.marketvisual.com/de/a4b8ffad-7f8f-49c5-a333-1cb8114032f2/Vita+34+International+AG



Blue Cross owned 7% of CBAI as of the end of last year. Don't know how much they currently own of CBAI. We also don't know who bought on those billion share trade days. And lastly, with Blue Cross having ownership in both companies (at least 35% of Vita 34 International AG) do you think they want Matt to come to Germany and start a new company. Follow the money. I have more.

This is what scares me when a small co tries to grow through acquisitions....its a tricky business... I must rather they build the business through sales...

http://www.edhec-mba.com/jsp/fiche_pagelibre.jsp?CODE=03370970&LANGUE=1

The play here is to buy Vita stock.....if the dots you guys are
" connecting " comes true...look for CBAI to tank and VITA to pick up...jmo


Guess we'll see

gla

Thats what would scare me, to much exposure to too many countries.

I mean " Slovenia "...lol

Germany took a beating in 09, 2010 they expect a little growth..but nothing to make up the loss in 09.

Its a tough market, that's one reason these co's don't make much money...at least for now.

Another thing is Matt, I like him and I think he's an honest guy. but as a business man forget it...jmo...all he has acquired so far has been bought by dilution...thats a fact. Co has been losing Millions....not all his fault, but to say he's a smart business man ?

I haven't seen proof of it..

Germany's 2010 forecast..

http://www.marketwatch.com/story/german-economy-seen-growing-at-14-in-2010-2010-01-27

But it would more than quadruple there revenue in one buy and give them expansion into Europe big time. And cash flow positive. What's not to like with an emerging company. I'm thinking Neeson is ready to come home.

I've just been playing with the ibox. You may want to view it again now.

Btw, would you do me a favour and request a chart here. Ask for ticker VTIAF since that is the ticker used by US traders.
http://stockcharts.com/help/doku.php?id=support:feedback:symbol_request





"Be kinder than necessary, for everyone you meet is fighting some kind of battle."

A lot of them seem to be having a tough time. You are correct there.

I'm in the midst of researching a number of them since I believe this industry will be huge in the future. I'll make my list of my top five to invest and hold when I'm done. ;) Just gathering data now.







"Be kinder than necessary, for everyone you meet is fighting some kind of battle."

Nice board !!

Marked it !

That is some scenario Dew....trouble is CBAI acquiring a break even co would probably drop CBAI's share price...happens all the time

Another stem cell co that's barely making ends meet...seems they all are in the same boat.

Please request chart here. Ask for ticker VTIAF since that is the ticker used by US traders.
http://stockcharts.com/help/doku.php?id=support:feedback:symbol_request






"Be kinder than necessary, for everyone you meet is fighting some kind of battle."

Read the Letter to Shareholders in the 3Q 2009 Vita 34 Quarterly Report at this web address. I like what I'm reading.




http://ir.vita34.de/cgi-bin/show.ssp?companyName=vita34&language=English&id=4200

Obviously, this is speculation. But perhaps Matt, the CEO of CBAI, needed some of the shares he just recooped from the S1 to close a deal such as Vita34 International AG. If for instance CBAI's share price went to just .03 after such announcement, Matt could file a new S1 and would only need to register 341M warrants/shares to get the full $7.5M. And remember if the warrants are turned into common shares Optimus would have to purchase the warrants which would bring in another $7.5M. So funding for deals are abundant right now. GLTA Longs

Seems to be deep connections between Cord Blood America (CBAI) and Vita 34 International AG. We know for sure CBAI is looking hard for acquisitions. Could this be the next one?

Dream about this. Read the very fine print at the bottom of page one of the first link. Sometimes following the money is not easy. But clearly Vita34 has some interesting connections to CBAI. For one, the Chairman of Vita34 International AG which owns Vita34 is Richard J. Neesan. Once a Director of CBAI and obviously put in his current position by Blue Cross Blue Shield a majority owner. Number two, Matt bought Corcell from Viata34 five years ago, so they have a history. I'm not smart enough to have an understanding how Matt could buy Vita34 International AG but I know he and Joe, COO of Cord Blood, spent two weeks in Germany last November. This would be a big deal and would take a lot time to close if in fact that is what is going on. That would be a dream. Now he's moving on to China already. Much will happen for investors here in 2010 IMO. Do your own DD.


http://parentsguidecordblood.org/content/media/m_pdf/vita34_mit_corcell.pdf


http://www.vita34.de/vita/en/

Richard Neeson http://www.zoominfo.com/people/Neeson_Richard_407627000.aspx?PersonID=407627000&lastName=Neeson&firstName=Richard&id=407627000&searchSource=page&page=3